<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Merck (MRK) And Daiichi Sankyo&#x27;s R-DXd Receives FDA Breakthrough Therapy Designation</title>
    <meta name="description" content="Current share prices reflect a discount of approximately 23.6% compared to the consensus analyst price target of US$102.33.; Over the past five years, Merck&#x27;s total shareholder return, incorporating both share price appreciation and dividends, was 21.17%.; Notably, its yearly performance has also been weaker compared to peers in the US Pharmaceuticals industry, which saw a 12.5% decline." />
    <link rel="alternate" type="application/rss+xml" title="Daily Finance Newsletter" href="https://suavir600.github.io/newsletter/feed.xml" />
    <style>
:root{--bg:#0b0f19;--fg:#e8ecf2;--muted:#93a1b1;--card:#121826;--accent:#4f8cff}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--fg);font:16px/1.55 system-ui,-apple-system,Segoe UI,Roboto,Ubuntu}
a{color:var(--accent);text-decoration:none} a:hover{text-decoration:underline}
.container{max-width:980px;margin:0 auto;padding:20px}
.nav{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.brand{font-weight:700} .muted{color:var(--muted)}
.grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(280px,1fr));gap:16px}
.card{background:var(--card);border-radius:16px;padding:16px;box-shadow:0 6px 20px rgba(0,0,0,.25)}
.card h3{margin:0 0 8px 0;font-size:1.05rem}
.badge{display:inline-block;background:#1c2335;color:#c0cad8;padding:.2rem .5rem;border-radius:999px;font-size:.75rem;margin-right:.4rem}
.btn{display:inline-block;background:var(--accent);color:#fff;padding:.5rem .75rem;border-radius:10px;font-weight:600}
.btn-outline{background:transparent;border:1px solid var(--accent);color:var(--accent)}
.list ul{margin:.5rem 0 0 1.2rem}
.footer{margin-top:36px;color:var(--muted);font-size:.9rem;text-align:center}
hr{border:none;border-top:1px solid #223; margin:16px 0}
</style>
  </head>
  <body>
    <div class="container">
      <div class="nav">
        <div class="brand"><a href="https://suavir600.github.io/newsletter">Daily Finance Newsletter</a></div>
        <div class="muted">5–7 key bullets per story</div>
      </div>
      
<h1>Merck (MRK) And Daiichi Sankyo&#x27;s R-DXd Receives FDA Breakthrough Therapy Designation</h1>
<div class="muted">2025-09-15 17:27:14+00:00</div>
<hr />
<div class="list"><ul>
  <li>Current share prices reflect a discount of approximately 23.6% compared to the consensus analyst price target of US$102.33.</li><li>Over the past five years, Merck&#x27;s total shareholder return, incorporating both share price appreciation and dividends, was 21.17%.</li><li>Notably, its yearly performance has also been weaker compared to peers in the US Pharmaceuticals industry, which saw a 12.5% decline.</li><li>This figure illustrates a steady growth trajectory, yet the company has underperformed the US market&#x27;s 18.5% return over the past year.</li><li>Merck experienced a 6% rise in its share price over the last quarter, coinciding with significant developments such as the FDA granting Breakthrough Therapy Designation for raludotatug deruxtecan—a potential first-in-cla</li><li>Find out which 28 stocks are leading the charge.</li><li>We&#x27;ve discovered 1 weakness for Merck that you should be aware of before investing here.</li>
</ul></div>
<div style="margin-top:12px">
  <a class="btn-outline" href="https://finance.yahoo.com/news/merck-mrk-daiichi-sankyos-r-172714735.html" target="_blank" rel="noopener">Original</a>
  <a class="btn" href="https://twitter.com/intent/tweet?text=Merck+%28MRK%29+And+Daiichi+Sankyo%27s+R-DXd+Receives+FDA+Breakthrough+Therapy+Designation%0A%E2%80%A2+Current+share+prices+reflect+a+discount+of+approximately+23.6%25+compared+to+the+consensus+analyst+price+target+of+US%24102.33.%0A%E2%80%A2+Over+the+past+five+years%2C+Merck%27s+total+s%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2Fnewsletter%2Farticles%2Fmerck-mrk-and-daiichi-sankyo-s-r-dxd-receives-fda-breakthrough-therapy-designati%2F" target="_blank" rel="noopener">Share on X</a>
</div>

      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </body>
</html>